Insider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells 25,037 Shares of Stock

Trevi Therapeutics, Inc. (NASDAQ:TRVIGet Free Report) CEO Jennifer L. Good sold 25,037 shares of the business’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $2.86, for a total transaction of $71,605.82. Following the transaction, the chief executive officer now owns 213,313 shares in the company, valued at $610,075.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Trevi Therapeutics Stock Down 2.9 %

Trevi Therapeutics stock opened at $2.65 on Thursday. The company has a market capitalization of $186.64 million, a P/E ratio of -7.79 and a beta of 0.91. The firm has a 50 day moving average price of $3.00 and a 200-day moving average price of $2.13. Trevi Therapeutics, Inc. has a twelve month low of $0.97 and a twelve month high of $4.00.

Trevi Therapeutics (NASDAQ:TRVIGet Free Report) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.02. Equities analysts expect that Trevi Therapeutics, Inc. will post -0.42 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on TRVI shares. Oppenheimer restated an “outperform” rating and set a $9.00 price target on shares of Trevi Therapeutics in a report on Thursday, March 21st. Needham & Company LLC reissued a “buy” rating and set a $8.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, May 8th.

Get Our Latest Report on TRVI

Institutional Trading of Trevi Therapeutics

A number of institutional investors have recently modified their holdings of TRVI. Price T Rowe Associates Inc. MD purchased a new stake in shares of Trevi Therapeutics during the 1st quarter valued at approximately $47,000. SG Americas Securities LLC lifted its stake in Trevi Therapeutics by 401.4% in the 4th quarter. SG Americas Securities LLC now owns 98,253 shares of the company’s stock worth $132,000 after purchasing an additional 78,656 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Trevi Therapeutics in the 1st quarter worth approximately $208,000. Propel Bio Management LLC purchased a new stake in Trevi Therapeutics in the 1st quarter worth approximately $897,000. Finally, Silverarc Capital Management LLC lifted its stake in Trevi Therapeutics by 4.7% in the 3rd quarter. Silverarc Capital Management LLC now owns 927,415 shares of the company’s stock worth $2,022,000 after purchasing an additional 41,491 shares in the last quarter. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Trevi Therapeutics Company Profile

(Get Free Report)

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.

Further Reading

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.